Trials / Terminated
TerminatedNCT04250597
Study of GNX102 in Patients With Advanced Solid Tumors
A Phase I Study of GNX102 in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- GlycoNex, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells. Specifically, GNX102 binds to novel glycan structures caused by glycosylation changes in tumors. Patients with epithelial origin cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GNX102 | Dose Escalation |
| DRUG | GNX102 | Expansion Phase |
Timeline
- Start date
- 2020-07-29
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
- First posted
- 2020-01-31
- Last updated
- 2024-05-06
Locations
8 sites across 2 countries: United States, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04250597. Inclusion in this directory is not an endorsement.